Esomeprazole or Famotidine in the Management of Aspirin Related Non-Ulcer Dyspepsia

This study is currently recruiting participants.
Verified June 2012 by Ruttonjee Hospital
Sponsor:
Collaborator:
Queen Mary Hospital, Hong Kong
Information provided by (Responsible Party):
Fook-Hong Ng, Ruttonjee Hospital
ClinicalTrials.gov Identifier:
NCT00978159
First received: September 15, 2009
Last updated: June 5, 2012
Last verified: June 2012
  Purpose

Aspirin can prevent ischemic vascular disease but is commonly complicated by dyspepsia in 30% of patients. Patients, who have aspirin related dyspepsia, commonly underwent upper endoscopy to exclude peptic ulcer disease or gastric cancers. For those without significant lesions in the stomach and duodenum (non-ulcer dyspepsia), the best approach in the management is unclear. The objective of this study is to compare the efficacy of esomeprazole and famotidine in the control of dyspeptic symptom. After giving consent, patients will be randomised to receive either esomeprazole 20 mg daily or famotidine 40 mg daily in a double blinded manner. The patient will be followed-up at the 2nd and 4th week. The study will be completed at the 4th week. The primary analysis will be the efficacy in the control of dyspepsia symptom between the two groups.


Condition Intervention Phase
Aspirin
Dyspepsia
Drug: esomeprazole
Drug: Famotidine
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Esomeprazole or Famotidine in the Management of Aspirin Related Non-ulcer Dyspepsia - a Double Blind Randomized Control Study

Resource links provided by NLM:


Further study details as provided by Ruttonjee Hospital:

Primary Outcome Measures:
  • Treatment success : The HKDI is less than 16. Treatment was considered to have failed if a patient had taken medication for dyspepsia (other than antacids) during the study period [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Treatment success: no significant dyspepsia defined by the Global Dyspepsia Score [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]

Estimated Enrollment: 128
Study Start Date: September 2009
Estimated Study Completion Date: December 2013
Estimated Primary Completion Date: December 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: esomeprazole
esomeprazole 20 mg
Drug: esomeprazole
esomeprazole 20 mg po for 4 weeks
Active Comparator: Famotidine
famotidine 40 mg
Drug: Famotidine
Famotidine 40 mg po for 4 weeks

Detailed Description:

The objective of this double blinded randomized controlled study is to compare the efficacy of esomeprazole with famotidine in the control of dyspepsia in patients with aspirin related nonulcer dyspepsia NUD.

Method

The study shall be applied for approval from the Ethic Committee of Hong Kong West and East Cluster and shall be registered to the Clinical Trial Governance before the recruitment of the first patient.

Measuring instruments & Definitions

Hong Kong Dyspepsia Index (HKDI)

The presence or absence of dyspepsia was measured by the validated Hong Kong index of dyspepsia . This questionnaire could be used in epidemiological studies assessing the frequency and severity of dyspepsia in patient populations and also in interventional studies in functional dyspepsia.This index consisted of 12 questions on the severity of gastrointestinal symptoms, graded according to a five-point Likert scale (1- 5, from asymptomatic to very severe symptoms). A cut-off score of equal to or greater than 16 was determined to discriminate between controls and dyspeptic patients.

Global Dyspepsia Score

The global severity of dyspepsia will be measured by the Global Dyspepsia Score, which was a four-point scale in which a score of 0 indicated no pain or discomfort, a score of 1 mild pain or discomfort, a score of 2 moderate (annoying but not interfering with the daily routine) pain or discomfort, and a score of 3 severe (markedly interfering with the daily routine) pain or discomfort over the last 7 days . This scale is reliable, valid, and responsive and provides global assessment of symptoms in the western population . Significant dyspepsia was defined when Global Dyspepsia Score was more than or equal to 2 moderate.

Definition of significant endoscopic finding

Significant finding was defined as the presence of reflux esophagitis, Barrett's esophagus, gastric or duodenal ulceration, duodenal or esophageal erosions, or cancer and those with more than five gastric erosions on upper endoscopy. (Tally N, NEJM 1999)

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • at least moderate pain or discomfort (or both) centered in the upper abdomen as their predominant symptoms for 7 days before randomization; taking low dose aspirin (80-300 mg daily),and insignificant upper endoscopic finding. At least moderate pain or discomfort is defined if the HKDI was more than or equal to 16.
  • H. Pylori: In patients with have successful eradication of H. pylori and had dyspepsia with HKDI >=16 at the 6th week after eradication therapy can be recruited.In patients without H. pylori infection, they can be recruited immediately.

Exclusion Criteria:

  • non-Chinese speaking
  • significant endoscopic finding
  • typical biliary colic
  • predominant heartburn or symptoms of the irritable bowel syndrome
  • a history of peptic ulcer or gastroesophageal reflux
  • unintentional weight loss previous gastric or duodenal surgery
  • thrombocytopenia
  • renal failure with estimated creatinine clearance less than 10 ml/min
  • active cancer
  • known allergic to aspirin, famotidine or esomeprazole
  • pregnancy, lactation, child-bearing potential in the absence of contraception
  • planned co-prescription of nonsteroidal anti-inflammatory drugs
  • corticosteroid, clopidogrel or anticoagulant
  • anxiety neurosis, depression, psychosomatic disorder
  • investigation for dyspepsia with endoscopy or barium series before aspirin therapy or disorders that might modify the absorption of study drugs
  • ongoing treatment with a histamine H2-receptor antagonist, a prostaglandin, or a prokinetic drug during the 7 days before enrollment was not permitted, nor was treatment with a proton-pump inhibitor, or bismuth in the 30 days before enrollment
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00978159

Contacts
Contact: FH Ng, M.D. 22911743 ngfhong@hkucc.hku.hk

Locations
China, Hong Kong
Queen Mary Hospital Recruiting
Pokfulam, Hong Kong, China
Contact: Ivan Hung    28551111      
China
Ruttonjee Hospital Recruiting
Hong Kong, China
Contact: FH Ng, MD    22911743      
Sponsors and Collaborators
Ruttonjee Hospital
Queen Mary Hospital, Hong Kong
Investigators
Principal Investigator: FH Ng, MD Ruttonjee Hospital
  More Information

No publications provided

Responsible Party: Fook-Hong Ng, CON, Ruttonjee Hospital
ClinicalTrials.gov Identifier: NCT00978159     History of Changes
Other Study ID Numbers: HKEC 2009-058
Study First Received: September 15, 2009
Last Updated: June 5, 2012
Health Authority: Hong Kong: Hospital Authority

Keywords provided by Ruttonjee Hospital:
esomeprazole
famotidine
aspirin
dyspepsia

Additional relevant MeSH terms:
Dyspepsia
Signs and Symptoms, Digestive
Signs and Symptoms
Aspirin
Omeprazole
Famotidine
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Pharmacologic Actions
Anti-Inflammatory Agents
Therapeutic Uses
Antirheumatic Agents
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action
Cardiovascular Agents
Hematologic Agents
Platelet Aggregation Inhibitors
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Antipyretics
Central Nervous System Agents
Anti-Ulcer Agents
Gastrointestinal Agents
Histamine H2 Antagonists
Histamine Antagonists

ClinicalTrials.gov processed this record on April 17, 2014